PROPOSED BUSINESS COMBINATION: Apexigen, Inc.
ENTERPRISE VALUE: $205 million
ANTICIPATED SYMBOL: APGN
Brookline Capital Acquisition Corporation proposes to combine with Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology,
- Apexigen’s wholly-owned pipeline is focused on antibody-based therapeutics for oncology, with an emphasis on new immuno-oncology agents that may focus on the patient’s immune system to combat and eradicate cancer.
...READ MORE